首页> 外文学位 >Protein aggregation in aqueous solution: Mechanism, thermodynamics, and kinetics.
【24h】

Protein aggregation in aqueous solution: Mechanism, thermodynamics, and kinetics.

机译:水溶液中的蛋白质聚集:机理,热力学和动力学。

获取原文
获取原文并翻译 | 示例

摘要

The aggregation of protein molecules into non-native assemblies in vivo can have profound pathological implications, as in the aggregation of amyloid-beta in Alzheimer's disease and the aggregation of alpha-synclein in Parkinson's disease. In the pharmaceutical industry, protein aggregation is routinely encountered during refolding, purification, sterilization, shipping, storage, and delivery. In addition to reducing efficacy, aggregates in parenterally administered proteins can cause adverse reactions in patients, such as immune response, anaphylactic shock, or even death. Stabilization of protein is particularly challenging because protein molecules are only marginally stable in aqueous solution.; We used recombinant human therapeutic proteins (granulocyte colony stimulating factor, platelet-activating factor acetylhydrolase, and interleukin-1 receptor antagonist) and amyloid disease-associated proteins (alpha-synuclein and immunoglobulin light chains) to probe the fundamental mechanism, thermodynamic driving forces, and kinetics by which proteins aggregate and by which varying solution conditions (e.g., temperature, pH, salts, cosolutes, preservatives, and surfactants) affect this process.; We found that protein aggregation involves at least two critical steps. The first requires perturbation to the protein's native structure to form an aggregation-competent intermediate, and proceeds through a structurally-expanded transition state. The second step involves the assembly of aggregation-competent intermediates to form aggregates. The energy barriers of the two steps are reflected in the values of free energy of unfolding (DeltaG unf) and osmotic second virial coefficient (B 22), respectively. Under conditions where conformational stability dominates, the first step is rate-limiting, and increasing Delta Gunf (e.g., by adding sucrose) decreases aggregation. In solution where colloidal stability is high, the second step is rate-limiting, and increasing repulsive interactions between proteins (e.g., by changing pH and ionic strength) is effective at reducing aggregation.; In addition to conformational and colloidal stability, protein surface activity can emerge to be an important factor controlling aggregation. Protein aggregation is inherently a nucleation and growth process during which soluble proteins assemble and precipitate into insoluble aggregates. Conditions affecting either nucleation or growth can alter protein aggregation behavior. High surface activity coupled with favorable protein-surface contacts can drive aggregation by inducing heterogeneous nucleation. (Abstract shortened by UMI.)
机译:蛋白质分子在体内向非天然组装体的聚集可能具有深远的病理学意义,例如在阿尔茨海默氏病中淀粉样β的聚集和帕金森氏病中α-synclein的聚集。在制药工业中,蛋白质的聚集通常在重新折叠,纯化,灭菌,运输,储存和输送过程中发生。除降低功效外,肠胃外施用的蛋白质中的聚集体还会引起患者的不良反应,例如免疫反应,过敏性休克甚至死亡。蛋白质的稳定化尤其具有挑战性,因为蛋白质分子仅在水溶液中稳定。我们使用了重组人类治疗性蛋白质(粒细胞集落刺激因子,血小板活化因子乙酰水解酶和白介素1受体拮抗剂)和淀粉样疾病相关蛋白质(α-突触核蛋白和免疫球蛋白轻链)来探究其基本机制,热力学驱动力,以及蛋白质聚集的动力学和变化的溶液条件(例如温度,pH,盐,溶质,防腐剂和表面活性剂)所影响的动力学。我们发现蛋白质聚集涉及至少两个关键步骤。首先需要扰动蛋白质的天然结构以形成具有聚集能力的中间体,然后继续进行结构扩展的过渡态。第二步涉及组装具有聚集能力的中间体以形成聚集体。这两个步骤的能垒分别反映在展开自由能(DeltaG unf)和渗透第二维里系数(B 22)的值中。在构象稳定性占优势的条件下,第一步是限速,增加Delta Gunf(例如,通过添加蔗糖)可减少聚集。在胶体稳定性高的溶液中,第二步是限速的,增加蛋白质之间的排斥相互作用(例如,通过改变pH和离子强度)可有效减少聚集。除了构象和胶体稳定性外,蛋白质表面活性可能成为控制聚集的重要因素。蛋白质聚集本质上是一种成核和生长过程,在此过程中可溶性蛋白质聚集并沉淀为不溶性聚集体。影响成核或生长的条件可以改变蛋白质聚集行为。高表面活性与良好的蛋白质-表面接触相结合,可以通过诱导异种成核来促进聚集。 (摘要由UMI缩短。)

著录项

  • 作者

    Chi, Eva Y.;

  • 作者单位

    University of Colorado at Boulder.;

  • 授予单位 University of Colorado at Boulder.;
  • 学科 Engineering Chemical.
  • 学位 Ph.D.
  • 年度 2004
  • 页码 333 p.
  • 总页数 333
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 化工过程(物理过程及物理化学过程);
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号